BIONXT SOLUTIONS INC. (BXT) - Net Assets
Based on the latest financial reports, BIONXT SOLUTIONS INC. (BXT) has net assets worth €-7.32 Million EUR (≈ $-8.55 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€333.75K ≈ $390.19K USD) and total liabilities (€7.65 Million ≈ $8.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See BXT net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-7.32 Million |
| % of Total Assets | -2192.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIONXT SOLUTIONS INC. - Net Assets Trend (2021–2025)
This chart illustrates how BIONXT SOLUTIONS INC.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BXT company net worth.
Annual Net Assets for BIONXT SOLUTIONS INC. (2021–2025)
The table below shows the annual net assets of BIONXT SOLUTIONS INC. from 2021 to 2025. Also explore BXT year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-9.37 Million ≈ $-10.95 Million |
-19.13% |
| 2024-12-31 | €-7.86 Million ≈ $-9.19 Million |
-48.82% |
| 2023-12-31 | €-5.28 Million ≈ $-6.18 Million |
-27.96% |
| 2022-12-31 | €-4.13 Million ≈ $-4.83 Million |
-347.41% |
| 2021-12-31 | €1.67 Million ≈ $1.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BIONXT SOLUTIONS INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2798866300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €62.00 Million | % |
| Total Equity | €-9.37 Million | 100.00% |
BIONXT SOLUTIONS INC. Competitors by Market Cap
The table below lists competitors of BIONXT SOLUTIONS INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ram Technology Co. Ltd
KQ:171010
|
$24.90 Million |
|
Optimi Health Corp. Common Shares
NASDAQ:OPTH
|
$24.91 Million |
|
Kyobo 3 SPAC
KQ:208710
|
$24.91 Million |
|
Ntaw Holdings Ltd
AU:NTD
|
$24.92 Million |
|
Hunyvers SA
PA:ALHUN
|
$24.90 Million |
|
Aetherium Acquisition Corp
NASDAQ:GMFI
|
$24.90 Million |
|
Eqva ASA
OL:EQVA
|
$24.89 Million |
|
Ropharma Bras
RO:RPH
|
$24.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIONXT SOLUTIONS INC.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -7,861,460 to -9,365,620, a change of -1,504,160.
- Net loss of 7,025,486 reduced equity.
- Other factors increased equity by 5,521,326.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.03 Million | -75.01% |
| Other Changes | €5.52 Million | +58.95% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares BIONXT SOLUTIONS INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.02 | €0.20 | x |
| 2022-12-31 | €-0.05 | €0.20 | x |
| 2023-12-31 | €-0.05 | €0.20 | x |
| 2024-12-31 | €-0.07 | €0.20 | x |
| 2025-12-31 | €-0.08 | €0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BIONXT SOLUTIONS INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-247.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -1236.76% | -7203.23% | 0.03x | 5.83x | €-20.80 Million |
| 2022 | 0.00% | -4160.84% | 0.18x | 0.00x | €-11.96 Million |
| 2023 | 0.00% | -2074.68% | 0.29x | 0.00x | €-7.19 Million |
| 2024 | 0.00% | -19683.18% | 0.05x | 0.00x | €-4.53 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-6.09 Million |
Industry Comparison
This section compares BIONXT SOLUTIONS INC.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,764,249,710
- Average return on equity (ROE) among peers: -103.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIONXT SOLUTIONS INC. (BXT) | €-7.32 Million | -1236.76% | N/A | $24.90 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.24 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| HANSOH PHARMAC. HD-00001 (3KY) | $35.36 Billion | 15.71% | 0.13x | $22.06 Billion |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $252.60 Million | -46.62% | 0.59x | $123.09 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-11.28 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $6.62 Million |
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-ag… Read more